Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 1.00 |
| ▸ | CDK9 | P50750 | 7/20 | 1.00 |
| ▸ | CDK7 | P50613 | 4/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 6/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.67 |
| ▸ | WEE1 | P30291 | 3/20 | 0.67 |
| ▸ | FLT3 | P36888 | 3/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.67 |
| ▸ | JAK2 | O60674 | 2/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.67 |
| ▸ | PAK4 | O96013 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | FYN | P06241 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 2/20 | 0.67 |
| ▸ | MET | P08581 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076008 | 0.90 | CDK2 (0.81) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL2076613 | 0.89 | CDK2 (0.80) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL2087938 | 0.86 | CDK2 (0.75) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL2087906 | 0.85 | CDK2 (0.75) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL2087407 | 0.84 | CDK2 (0.71) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL2087314 | 0.84 | CDK2 (0.71) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL2074623 | 0.83 | CDK2 (0.81) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL2086730 | 0.82 | GSK3B (0.70) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL2086354 | 0.82 | CDK2 (0.68) | CDK2CDK9CDK7CCNT1AURKA | |
| SCHEMBL4167442 | 0.81 | CDK2 (0.80) | CDK2CDK9CDK7CCNT1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | claimed |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-09-05 | — | — | US | claimed |
| EP-3686290-B1 | METHOD AND KITS FOR IDENTIFYING CDK9 INHIBITORS FOR THE TREATMENT OF CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2022261220-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-15 | — | — | WO | claimed |
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | claimed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | claimed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250041303-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-02-06 | — | — | US | disclosed |
| EP-4440623-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | disclosed |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-09-05 | — | — | US | disclosed |
| EP-3686290-B1 | METHOD AND KITS FOR IDENTIFYING CDK9 INHIBITORS FOR THE TREATMENT OF CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20080125404-A1 | purine and pyrimidine derivatives such as Roscovitine or 2-[(1-ethyl-2-hydroxyethyl)amino]-6-benzylamine-9-isopropylpurine or olomoucine or purvalanol A for treating human systemic lupus erythematosus associated with antinuclear antibodies; methylprednisolone | CYCLACEL LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080125404-A1 | purine and pyrimidine derivatives such as Roscovitine or 2-[(1-ethyl-2-hydroxyethyl)amino]-6-benzylamine-9-isopropylpurine or olomoucine or purvalanol A for treating human systemic lupus erythematosus associated with antinuclear antibodies; methylprednisolone | CYCLACEL LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| WO-2007054725-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054725-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | BCL3, MCL1, BCL2 | CDK2 741/4885CDK9 1739/4885CDK7 2337/4885 |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | MCL1, BCL3, CRBN | CDK2 1951/4885CDK9 2105/4885CDK7 2426/4885 |
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | CDK2 52/4885CDK9 5/4885CDK7 158/4885 |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | CDK2 459/4885CDK9 1001/4885CDK7 1077/4885 |
| US-20080125404-A1 | purine and pyrimidine derivatives such as Roscovitine or 2-[(1-ethyl-2-hydroxyethyl)amino]-6-benzylamine-9-isopropylpurine or olomoucine or purvalanol A for treating human systemic lupus erythematosus associated with antinuclear antibodies; methylprednisolone | CDK9, SSB, CDK7 | CDK2 6/4885CDK9 1/4885CDK7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.